Gastrointestinal stromal tumor (GIST) is one of the most common cancers of the digestive tract. Surgical resection is critical to cure patients, but without additional therapies the risk of recrudescence may be great. Particularly for high-risk patients, targeted therapies utilizing type III tyrosine kinase inhibitors (TKI) minimize the probability of recurrence. TKI therapies although generally well tolerated, have several potential side effects and carry significant economic costs.
Endoscopic resection is an emerging therapy used to treat gastrointestinal stromal tumors. Endoscopic resection, particularly for smaller tumors (less than 2 cm) appears to be safe and effective in many patients. The use of this procedure is supported by a growing body of data supporting equivalency of endoscopic resection versus surgical outcomes. Work now is examining endoscopic resection for larger tumors.
This Research Topic aims to collect novel studies that can better assess the risk of recrudescence of gastrointestinal stomal tumors based on individual patients’ profiles, diagnosis, and specific tumor characteristics. Furthermore, we welcome research that compares different treatments, in order to advance the development of solid guidelines for the management of gastrointestinal stromal tumors that can serve to improve post-surgical outcomes.
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Gastrointestinal stromal tumor (GIST) is one of the most common cancers of the digestive tract. Surgical resection is critical to cure patients, but without additional therapies the risk of recrudescence may be great. Particularly for high-risk patients, targeted therapies utilizing type III tyrosine kinase inhibitors (TKI) minimize the probability of recurrence. TKI therapies although generally well tolerated, have several potential side effects and carry significant economic costs.
Endoscopic resection is an emerging therapy used to treat gastrointestinal stromal tumors. Endoscopic resection, particularly for smaller tumors (less than 2 cm) appears to be safe and effective in many patients. The use of this procedure is supported by a growing body of data supporting equivalency of endoscopic resection versus surgical outcomes. Work now is examining endoscopic resection for larger tumors.
This Research Topic aims to collect novel studies that can better assess the risk of recrudescence of gastrointestinal stomal tumors based on individual patients’ profiles, diagnosis, and specific tumor characteristics. Furthermore, we welcome research that compares different treatments, in order to advance the development of solid guidelines for the management of gastrointestinal stromal tumors that can serve to improve post-surgical outcomes.
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
